GSK buys full rights to make COVID, influenza vaccines from CureVac
Wednesday, July 3rd 2024, 6:25:52 am
article
The deal is the result of restructuring a collaboration, which began in 2020 to develop mRNA-based vaccines for infectious diseases, into a new licensing agreement, GSK added. As a result of the collaboration, the two companies have vaccine candidates for seasonal influenza and COVID-19 in phase II clinical development and avian influenza in phase I clinical development.
Breaking
The new preferred stock offering, SATA, strengthens Strive’s capital options as it expands its bitcoin focused strategy....
Now, citizens on the street attack the bounty hunters and release the 'recruits'....
A Sudanese IL-76 cargo plane has crashed near Port Sudan, killing all crew members, according to local sources...
